New hope for diabetic eye disease: experimental drug SNP318 enters Mid-Stage trial
Disease control
Not yet recruiting
This study tests an experimental drug called SNP318 in 60 people with diabetic macular edema, a condition that causes vision loss due to swelling in the retina. Participants will receive either the drug or a placebo, and researchers will monitor safety, eye thickness, and vision …
Phase: PHASE2 • Sponsor: SciNeuro • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC